By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nordic Nanovector 

Kjelsåsveien 168 B

  Oslo  0884  Norway
Phone: 47-22-18-33-01 Fax: 47-22-58-00-07


Company News
Nordic Nanovector And Areva Med To Investigate Potential Of Lead-212 Conjugated Anti-Cd37 Antibody For Treating Leukaemias 6/28/2016 11:44:59 AM
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin¬ģ Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity 6/10/2016 10:38:14 AM
BIO2016: Nordic Nanovector To Present At BIO International Convention On 7 June 2016 6/3/2016 10:21:52 AM
Nordic Nanovector: Allotment Of Restricted Stock Unites (RSUs) To The Board Of Directors 5/31/2016 1:01:01 PM
Nordic Nanovector Capital Markets Day 2016 To Highlight Strong Progress Towards Vision Of Becoming A Significant Player In Haematological Cancers 5/31/2016 10:35:50 AM
Nordic Nanovector To Host Capital Markets Day In Oslo On 31 May 2016 5/23/2016 9:39:21 AM
Nordic Nanovector: New Board Members Elected Bringing Further Expertise In The Development And Commercialization Of Innovative Cancer Therapies 5/23/2016 9:00:23 AM
Nordic Nanovector: Annual General Meeting Held 5/19/2016 12:07:38 PM
Nordic Nanovector First Quarter 2016 Results: Strong Progress On All Priorities And Execution On Track 5/19/2016 12:04:10 PM
Nordic Nanovector Announces First Patient Enrolled In The Last Cohort (Arm 4) Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients 5/18/2016 9:19:36 AM